Table of Content

1 INTRODUCTION (Page No. - 20)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 SUMMARY OF CHANGES
    1.7 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 25)
    2.1 SECONDARY DATA
           2.1.1 SECONDARY SOURCES
    2.2 PRIMARY DATA
           2.2.1 KEY DATA FROM PRIMARIES
           2.2.2 PRIMARY INSIGHTS
    2.3 MARKET SIZE ESTIMATION
    2.4 MARKET GROWTH RATE PROJECTIONS
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.6 RESEARCH ASSUMPTIONS
    2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 33)

4 PREMIUM INSIGHTS (Page No. - 38)
    4.1 HPAPI: MARKET OVERVIEW
    4.2 HPAPI MARKET, BY TYPE, 2021 VS. 2027 (USD BILLION)
    4.3 HPAPI MARKET, BY TYPE OF SYNTHESIS, 2021 VS. 2027 (USD BILLION)
    4.4 HPAPI MARKET BY THERAPEUTIC AREA (2021–2027)
    4.5 GEOGRAPHICAL SNAPSHOT OF HPAPI MARKET

5 MARKET OVERVIEW (Page No. - 43)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing demand for oncology drugs
                    5.2.1.2 Growing demand for antibody-drug conjugates
                    5.2.1.3 Increasing focus of leading pharmaceutical companies on HPAPIs
                    5.2.1.4 Advancements in HPAPI manufacturing technologies
                    5.2.1.5 Growing focus on precision medicine
           5.2.2 RESTRAINTS
                    5.2.2.1 Increasing requirement of large investments for employee safety
                    5.2.2.2 Discrepancies in HPAPI banding systems
                    5.2.2.3 Rising number of uncertainties associated with products
                    5.2.2.4 High risk of cross-contamination
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing opportunities for CMOs and CDMOs
                    5.2.3.2 Increasing opportunities for companies in emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Need for appropriate process designs
                    5.2.4.2 Constant evolution of industry standards and technologies
    5.3 IMPACT OF COVID-19 ON HPPAI MARKET
    5.4 REGULATORY ANALYSIS
           5.4.1 HANDLING HPAPI
           5.4.2 THIRD PARTY CERTIFICATION
           5.4.3 CONTAINMENT STRATEGIES
           5.4.4 CHALLENGES
    5.5 PORTER’S FIVE FORCES ANALYSIS
           5.5.1 THREAT OF NEW ENTRANTS
           5.5.2 THREAT OF SUBSTITUTES
           5.5.3 BARGAINING POWER OF SUPPLIERS
           5.5.4 BARGAINING POWER OF BUYERS
           5.5.5 DEGREE OF COMPETITION
    5.6 TECHNOLOGY ANALYSIS
           5.6.1 HANDLING POTENT COMPOUNDS
           5.6.2 CONTROLS
           5.6.3 SAFETY ASSESSMENT AND STANDARD OPERATING PROCEDURES
           5.6.4 DEDICATED EQUIPMENT AND SYSTEMS
           5.6.5 EXPERTISE AND TRAINING
           5.6.6 COMBUSTIBLE DUST HANDLING
           5.6.7 SUITABLE PERSONAL PROTECTIVE EQUIPMENT

6 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS CLASSIFICATION AND OVERVIEW (Page No. - 57)
    6.1 INTRODUCTION
    6.2 HPAPI INGREDIENTS CLASSIFICATION AS PER SAFEBRIDGE CONSULTANTS

7 HPAPI MARKET, BY TYPE (Page No. - 60)
    7.1 INTRODUCTION
    7.2 INNOVATIVE HPAPIS
    7.3 GENERIC HPAPIS

8 HPAPI MARKET, BY TYPE OF SYNTHESIS (Page No. - 67)
    8.1 INTRODUCTION
    8.2 SYNTHETIC APIS
           8.2.1 SYNTHETIC APIS MARKET, BY TYPE
    8.3 BIOTECH APIS
           8.3.1 BIOTECH APIS MARKET, BY TYPE
           8.3.2 BIOTECH APIS MARKET, BY PRODUCT
           8.3.3 VACCINES
           8.3.4 RECOMBINANT PROTEINS

9 HPAPI MARKET, BY TYPE OF MANUFACTURER (Page No. - 87)
    9.1 INTRODUCTION
    9.2 CAPTIVE HPAPI MANUFACTURERS
    9.3 MERCHANT HPAPI MANUFACTURERS
           9.3.1 MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE
           9.3.2 MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
           9.3.3 SYNTHETIC APIS
           9.3.4 BIOTECH APIS

10 HPAPI MARKET, BY THERAPEUTIC APPLICATION (Page No. - 104)
     10.1 INTRODUCTION
     10.2 ONCOLOGY
     10.3 HORMONAL IMBALANCE
     10.4 GLAUCOMA
     10.5 OTHER THERAPEUTIC APPLICATIONS

11 HPPAI MARKET, BY REGION (Page No. - 116)
     11.1 INTRODUCTION
     11.2 NORTH AMERICA
             11.2.1 US
             11.2.2 CANADA
     11.3 EUROPE
             11.3.1 GERMANY
             11.3.2 FRANCE
             11.3.3 UK
             11.3.4 ITALY
             11.3.5 SPAIN
             11.3.6 REST OF EUROPE
     11.4 ASIA
             11.4.1 JAPAN
             11.4.2 CHINA
             11.4.3 INDIA
             11.4.4 REST OF ASIA
     11.5 REST OF THE WORLD

12 COMPETITIVE LANDSCAPE (Page No. - 198)
     12.1 OVERVIEW
     12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
     12.3 MARKET SHARE ANALYSIS
     12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
     12.6 FOOTPRINT OF COMPANIES
     12.7 REGIONAL FOOTPRINT
     12.8 COMPETITIVE SCENARIO

13 COMPANY PROFILES (Page No. - 209)
     13.1 MAJOR PLAYERS
             13.1.1 PFIZER INC.
                       13.1.1.1 Business overview
                       13.1.1.2 Products offered
                       13.1.1.3 Recent developments
                       13.1.1.4 MnM view
                                   13.1.1.4.1 Key strengths/right to win
                                   13.1.1.4.2 Strategic choices
                                   13.1.1.4.3 Weaknesses and competitive threats
             13.1.2 NOVARTIS INTERNATIONAL AG
                       13.1.2.1 Business overview
                       13.1.2.2 Products offered
                       13.1.2.3 Recent developments
                       13.1.2.4 MnM view
                                   13.1.2.4.1 Key strengths/right to win
                                   13.1.2.4.2 Strategic choices
                                   13.1.2.4.3 Weaknesses and competitive threats
             13.1.3 SANOFI
                       13.1.3.1 Business overview
                       13.1.3.2 Products offered
                       13.1.3.3 Recent developments
                       13.1.3.4 MnM view
                                   13.1.3.4.1 Key strengths/right to win
                                   13.1.3.4.2 Strategic choices
                                   13.1.3.4.3 Weaknesses and competitive threats
             13.1.4 F. HOFFMANN-LA ROCHE
                       13.1.4.1 Business overview
                       13.1.4.2 Products offered
                       13.1.4.3 Recent developments
                       13.1.4.4 MnM view
                                   13.1.4.4.1 Key strengths/right to win
                                   13.1.4.4.2 Strategic choices
                                   13.1.4.4.3 Weaknesses and competitive threats
             13.1.5 BRISTOL-MYERS SQUIBB COMPANY
                       13.1.5.1 Business overview
                       13.1.5.2 Products offered
                       13.1.5.3 Recent developments
                       13.1.5.4 MnM view
                                   13.1.5.4.1 Key strengths/right to win
                                   13.1.5.4.2 Strategic choices
                                   13.1.5.4.3 Weaknesses and competitive threats
             13.1.6 BOEHRINGER-INGELHEIM
                       13.1.6.1 Business overview
                       13.1.6.2 Products offered
                       13.1.6.3 Recent developments
             13.1.7 TEVA PHARMACEUTICAL INDUSTRY LTD.
                       13.1.7.1 Business overview
                       13.1.7.2 Products offered
                       13.1.7.3 Recent developments
             13.1.8 ELI LILY AND COMPANY
                       13.1.8.1 Business overview
                       13.1.8.2 Products offered
                       13.1.8.3 Recent developments
             13.1.9 MERCK & CO., INC.
                       13.1.9.1 Business overview
                       13.1.9.2 Products offered
                       13.1.9.3 Recent developments
             13.1.10 ABBVIE INC.
                       13.1.10.1 Business overview
                       13.1.10.2 Products offered
             13.1.11 VIATRIS INC.
                       13.1.11.1 Business overview
                       13.1.11.2 Products offered
                       13.1.11.3 Recent developments
             13.1.12 BAYER
                       13.1.12.1 Business overview
                       13.1.12.2 Products offered

14 APPENDIX (Page No. - 265)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS